Deals and Partnerships

Partners in ALS ONE Join Forces to Advance Therapies for ALS

The ALS ONE partnership, founded in January 2016 by the late ALS patient Kevin Gosnell (see Jan 2016 news), has received a $2M funding commitment from the ALS Association to support ALS ONE initiatives. The Massachusetts-based partnership was founded to bring together leaders in the field of ALS from Massachusetts General Hospital, the ALS Therapy Development Institute (ALS TDI), […]

Read more »


Kadimastem Partners with Hadassah Medical Center for ALS Clinical Trial 

Israeli biotechnology company Kadimastem has finalized an agreement with Hadassah Ein-Kerem Medical Center in Israel for conducting its first human stem cell therapy for the treatment of ALS. The therapy, called AstroRx, uses stem-cell-derived astrocytes, which are delivered intrathecally, to provide trophic support to degenerating motor neurons. Preclinical studies in ALS rat models have shown […]

Read more »


Amylyx Secures Series A Financing for Phase II Trial in ALS

Cambridge, MA-based Amylyx Pharmaceuticals Inc. announced that it has secured a $5M Series A financing round to support its Phase II trial of AMX0035 in ALS.  The trial will test efficacy of this combination drug of sodium phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA), both of which have individually been tested in ALS clinical trials, and have shown efficacy in […]

Read more »


NeuroBANK™ Program to be Expanded With Large Grant

The NeuroBANK™ program at the Neurological Clinical Research Institute (NCRI) has received $3.6M in funding from The ALS Association, Massachusetts General Hospital (MGH), and ALS Finding A Cure  to support its expansion over the next 3 years. NeuroBANK is a patient-centric clinical research platform that facilitates integration of information across research projects, and provides core services for clinical […]

Read more »